Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 ...

Around 1.2 million Australians live with type 2 diabetes, yet there is no government subsidy for CGMs, despite this being well-established ...

Glucotrack (Nasdaq:GCTK) today provided an update on the planned regulatory timeline for its continuous blood glucose monitor ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 ...

Since its launch in 2025, more than one million users have adopted the Ottai CGM.

A trial testing new treatments aimed at restoring warning signs of low blood glucose in people with type 1 diabetes when ...

Chronic disease management stands at an inflection point. Globally, the number of people living with diabetes continues to climb, and healthcare systems in both developed and emerging markets are ...

Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...

SiBionics shared new findings about the use of AI in continuous glucose monitor (CGM) technologies at ATTD 2026.

We ask top nutrition experts to dig into the science behind the trend.

Dresden, FreeStyle Libre 3 sensor and app on the smartphone. The CGM device is measuring the glucose in the tissue and sending data to the digital health application.(Getty Images/Felix Geringswald) ...